Eton Pharmaceuticals (ETON) Set to Announce Earnings on Thursday

Eton Pharmaceuticals (NASDAQ:ETON) is expected to release its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of $0.3125 per share and revenue of $41.97 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings results on Thursday, August 13th. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.24. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 40.13%. The company had revenue of $37.59 million during the quarter, compared to the consensus estimate of $27.11 million. On average, analysts expect Eton Pharmaceuticals to post $1.13 EPS for the current fiscal year and $1.94 EPS for the next fiscal year.

Eton Pharmaceuticals Stock Down 2.6%

Shares of ETON opened at $50.81 on Tuesday. Eton Pharmaceuticals has a 52 week low of $14.27 and a 52 week high of $66.37. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of 133.71 and a beta of 0.90. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.30 and a current ratio of 1.52. The stock has a fifty day moving average of $55.75 and a 200-day moving average of $35.74.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Canaccord Genuity Group increased their target price on Eton Pharmaceuticals from $60.00 to $68.00 and gave the company a “buy” rating in a research report on Friday, August 14th. Zacks Research upgraded Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 12th. B. Riley Financial restated a “buy” rating and set a $70.00 price target (up from $40.00) on shares of Eton Pharmaceuticals in a report on Friday, August 14th. Craig Hallum reaffirmed a “buy” rating and issued a $78.00 price objective on shares of Eton Pharmaceuticals in a research note on Thursday, October 15th. Finally, Weiss Ratings upgraded Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research report on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Eton Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $71.50.

Insiders Place Their Bets

In related news, insider David Krempa sold 4,166 shares of Eton Pharmaceuticals stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $55.07, for a total transaction of $229,421.62. Following the completion of the transaction, the insider owned 43,381 shares of the company’s stock, valued at $2,388,991.67. This trade represents a 8.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Paul V. Maier sold 50,000 shares of the business’s stock in a transaction on Friday, August 28th. The shares were sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the completion of the transaction, the director owned 59,745 shares in the company, valued at approximately $3,529,137.15. The trade was a 45.56% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 79,166 shares of company stock worth $4,809,672. Insiders own 16.49% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton’s commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate.